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In one of his final essays, statesman and former United Nations secretary general Kofi Annan
said, ‘Snakebite is the most important tropical disease you’ve never heard of’ [1]. Mr. Annan
firmly believed that victims of snakebite envenoming should be recognised and afforded
greater efforts at improved prevention, treatment, and rehabilitation. During the last years of
his life, he advocated strongly for the World Health Organisation (WHO) and the global com-
munity to give greater priority to this disease of poverty and its victims.
Snakebite envenoming (SBE) affects as many as 2.7 million people every year, most of
whom live in some of the world’s most remote, poorly developed, and politically marginalised
tropical communities [2]. With annual mortality of 81,000 to 138,000 and 400,000 surviving
victims suffering permanent physical and psychological disabilities, SBE is a disease in urgent
need of attention [2–4]. Like many diseases of poverty, SBE has failed to attract requisite public
health policy inclusion and investment for driving sustainable efforts to reduce the medical
and societal burden. This is largely due to the demographics of the affected populations and
their lack of political voice [5].
Devising a consensual pathway to the goal of halving deaths and
disability by 2030
Despite decades of concern over the impact of SBE in low-middle-income countries (LMICs),
a lack of any clear mandate from member states has made it difficult for WHO to take substan-
tial action [4, 6–9]. Indeed, it wasn’t until 2015 when alarm over the possible therapeutic vac-
uum in Africa, caused by Sanofi-Pasteur’s decision to cease production of their FAV-Afrique
antivenom, galvanised renewed calls for urgent action [9, 10]. In 2017, after intense advocacy
by concerned stakeholders including Me´decins Sans Frontières [10, 11], the Global Snakebite
Initiative [5, 12–14], Health Action International, and a detailed submission by more than 20
countries, WHO listed SBE as a priority neglected tropical disease (NTD) [15, 16]. In May
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2018, the 71st World Health Assembly adopted a robust resolution (WHA71.5) on SBE, pro-
viding WHO with a strong mandate to take action [17].
The inclusion of SBE in the WHO NTD portfolio donates powerful attention to this disease.
Even before the resolution was adopted, WHO’s Department of the Control of Neglected
Tropical Diseases had already established a 28-member SBE Working Group (SBE-WG) to
support WHO in drafting a road map to implement strategies to prevent, reduce, and control
the snakebite burden. In June 2018, WHO convened a Wellcome-hosted meeting of the
SBE-WG to review a first draft of the road map document.
Central to the design of this strategic plan is the ambitious goal of halving the deaths and
disability caused SBE by 2030 (Fig 1). The consensus of the SBE-WG was that implementing
an integrated program based on building capacity and directing response to snakebite-affected
regions offers the most effective approach to achieving this goal. Rather than risk this initiative
being perceived as a standalone issue, the SBE-WG considered that efforts to combat SBE need
to be incorporated within national and regional health plans and aligned with global commit-
ments to achieving universal health coverage and the Sustainable Development Goals (SDG).
With this in mind, four key pillars (Fig 1; Table 1) have been prioritised:
1. Ensuring that safe and effective treatment is accessible and affordable for all;
2. Empowering regional, national, and local communities to take proactive action;
3. Strengthening health systems to deliver better outcomes; and
4. Building a strong global coalition of partners to build advocacy, mobilise resources, coordi-
nate action, and ensure that implementation of the roadmap is successful.
The scale of this challenge is considerable and its achievement requires a globally coordi-
nated and implemented strategy, with the WHO best positioned to coordinate this effort.
Safe and effective treatment
SBE is a medical emergency that particularly afflicts the world’s poorest people living in com-
munities with the lowest quality of life indices [18]. The sooner a victim receives effective treat-
ment, the greater the likelihood of a full recovery and an early return to normal life. For more
than 120 years, the cornerstone of snakebite treatment has been the administration of animal-
derived immunoglobulins (antivenoms) [2]. Most antivenoms are produced from the hyper-
immune plasma of horses or sheep, and the methods used have changed very little in the last
50 to 60 years [19]. Consequently, the quality and safety of some antivenoms remain poor. Pro-
duction inefficiencies, inadequate market demand, low manufacturing volumes, storage limi-
tations, and distribution problems have combined with inadequate funding for procurement,
poor health-worker training, and local bias towards traditional healing to create a fragile mar-
ket at risk of collapse in many parts of the world [20]. These market fragilities explain why, for
much of the last century, antivenom production has largely been the domain of public health
laboratories, few of which have been adequately capitalised to keep pace with modern pharma-
ceutical manufacturing technologies. And while private manufacturers have gained an increas-
ingly important role during the last four decades, especially in Asia and in Africa, the nature of
the market limits their capacity to resource infrastructure and innovation [20, 21]. As a conse-
quence, there has previously been little incentive for innovation or investment in new
technology.
Comprehensively addressing these issues is a key priority for WHO. The SBE-WG, con-
cerned by the current critical situation in sub-Saharan Africa, have set a target of delivering at
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least 500,000 effective antivenom treatments to that region each year by 2024. By the end of
2030, the target is to deliver, globally, 3 million effective regionally specific treatments per year.
To achieve this, WHO will work to strengthen the production of antivenoms, improve
Fig 1. Summary of WHO snakebite envenoming road map objectives, impact goals, and timeline phases.
https://doi.org/10.1371/journal.pntd.0007059.g001
Table 1. Summary of overall program areas.
Objective Safe and effective treatment Empowering and Engaging
communities
Stronger health systems Partnership, coordination and
resources
Key
activities
Programme-wide resource mobilisation to support all WHO activities and work plans
Make safe, effective antivenoms
available, accessible, and affordable
to all
Active community engagement and
participation
Strengthening community health
services
Supporting governance and
leadership
Better control and regulation of
antivenoms
Improve SBE prevention, risk-
reduction and avoidance
Facilitating research and policy
development around healthcare cost
mitigation
Promoting advocacy, effective
communication and productive
engagement
Prequalification of antivenoms Effective prehospital care and
ambulance transport
Improving infrastructure, services
and health facilities
Enhancing integration,
coordination and cooperation
Integrated health worker training
and education
Accelerate development of prehospital
treatments
Country-level implementation via
national and sub-national health
plans
Build strong regional partnerships
and alliances
Improving clinical decision-
making, treatment, recovery and
rehabilitation
Improve health care-seeking
behaviours
Enhanced disease burden
monitoring and surveillance
Coordinated data management and
analysis
Investing in innovative research on
new therapeutics
Build a strong understanding of socio-
cultural and economic factors affecting
outcomes
Research on SBE ecology,
epidemiology, clinical outcomes and
therapeutics
Research to build a strong and
sustainable investment case
https://doi.org/10.1371/journal.pntd.0007059.t001
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regulatory control, and most importantly, rebuild and reinvigorate the market by ensuring
that safe and effective products are available, accessible, and affordable.
WHO has already begun this process by undertaking a comprehensive product risk
assessment for sub-Saharan Africa. Its results are expected to be published in early 2019.
This evaluation included robust preclinical evaluation of products and site inspections to
evaluate compliance with good manufacturing practice (GMP). The result will be a WHO-
recommended list of products suitable for procurement across sub-Saharan Africa, provid-
ing purchasers and end-users with confidence that products are fit-for-use, and providing
manufacturers with incentive to improve the quality of products and comply with GMP and
other regulatory requirements as a pathway to restoring investment confidence in the mar-
ket and generating income commensurate with sustained delivery. As funding becomes
available, WHO plans to undertake similar antivenom risk–benefit assessments for other
regions and to consider the introduction of antivenom prequalification as a tool for further
strengthening the production of these life-saving drugs. Such a pathway will only be possi-
ble if technical barriers—such as the need to establish appropriate reference standards, min-
imum product design specifications, and pathways for acquiring robust clinical evidence—
are resourced and overcome.
A range of other initiatives (Box 1) will also be implemented to reinvigorate investment in
antivenom production and to establish an environment that attracts new manufacturers, stim-
ulates research, and encourages innovation. WHO will take key lessons from highly effective
vaccine stockpiling ventures, such as the Oral Cholera Vaccine Stockpile [22, 23], to model
and then establish an African Antivenom Stockpile as a pathway to creating a stable supply of
quality-assured WHO-recommended antivenom products in sub-Saharan Africa. This stock-
pile is designed to reshape the current market: converting it from one in which low production
at high unit cost has driven weak demand and distribution that culminated in poor accessibil-
ity and affordability; to one in which there is equitable access and affordability because of
higher production at lower cost as a result of increased market confidence, higher demand,
improved procurement, and wider distribution.
The SBE-WG also agreed that there needs to be a range of actions to encourage increased col-
laboration between academia, clinicians, and industry to improve potency, specificity, and safety
of current antivenoms, with an additional focus on development of new treatments. Research
involving robust preclinical and clinical evaluation of antivenoms and other treatments for SBE
will be encouraged, with clinical research prioritised for funding investment along with identify-
ing sentinel sites where clinical trials can be conducted to high standards. Refining preclinical
models to improve their reliability and relevance, and wider adoption of the 3R’s (reduction,
refinement, and replacement) relating to the use of experimental animals in the production and
testing of antivenoms are research priorities. With promising preclinical research on new thera-
peutic solutions to SBE management emerging, the need for investment in next generation ther-
apies and diagnostics also needs funding support [24, 25]. The WHO will work with antivenom
manufacturers, with national regulatory agencies, and with ministries of health to build capacity
to ensure that all treatments for SBE are properly controlled and regulated.
The SBE-WG also concurred that any effort to control the SBE burden requires broader
efforts at improving the overall management of snakebite victims. It is essential that standard
approaches be developed and implemented across all tiers of health systems. There should be
clear criteria for judging the success (or otherwise) of treatment. Currently there is little assis-
tance or support available to SBE survivors suffering residual disability. Establishment of dedi-
cated rehabilitation programs, addressing both psychological and physical disability, will
improve recovery of survivors, enabling more of them to return to useful, productive lives,
therefore increasing economic productivity.
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Box 1. Priority actions to ensure sustainable supply and accessibility
of safe, effective, and affordable antivenoms
Resource actions
• Identify and mobilise resources to reshape the market for sustained antivenom
delivery;
• Galvanise funding for research to improve existing antivenom technologies;
• Prioritise investment in clinical research, including clinical trials of the safety and
effectiveness of treatments;
• Increase resources to reduce treatment-associated patient financial and social
vulnerability.
Actions to improve quality, safety, and effectiveness of antivenoms
• Global risk–benefit assessments of antivenom products to ensure that at least three
quality-assured and fit-for-use antivenoms are accessible in each region;
• Strengthen the capacities of antivenom manufacturers to increase production,
improve research and development, and meet GMP and quality control requirements
and compliance with regulatory standards;
• Development and introduction of target product profiles (TPP’s), venom and anti-
venom reference standards, and an appropriate prequalification pathway;
• Provide essential guidance, regulatory and technical support to National Regulatory
Authorities (NRAs), National Control Laboratories (NCLs), and National Health
Authorities (NHAs) to strengthen and build capacity for effective regulation of anti-
venoms in all regions;
• Stimulate enhanced collaboration between research and manufacturing sectors to
improve all aspects of antivenom design, production, quality control, and evaluation.
Actions to increase accessibility and affordability of antivenoms
• Establish an antivenom stockpile programme initially for countries in sub-Saharan
Africa;
• Working with countries, partners and donors, apply a range of initiatives (in addition
to establishing revolving stockpiles) to reshape regional antivenom markets, increase
confidence, incentivise demand, and expand the availability, accessibility, and afford-
ability of WHO-recommended antivenoms;
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Empowering and engaging communities
As well as effective engagement with health decision makers at regional and national levels,
there is strong evidence linking the success of disease interventions to engagement with local
communities to engender trust in outcomes and hence productive participation [26–28]. A
major barrier to improving the treatment of SBE is the perception across many LMIC commu-
nities that rather than being a physical illness amenable to medical treatment, snakebites, like
many other unexpected illnesses, are associated with deity punishment, witchcraft, or other
powerfully persuasive phenomena that are often very locally specific [29, 30]. Context-appro-
priate engagement with local communities is therefore important to overcome these miscon-
ceptions and create a balance between traditional customs and modern healthcare. It is equally
vital that local hospitals and/or health centres are equipped with effective, affordable, and safe
antivenom. Funding should be made available to study the human–snake conflict interface,
the social and cultural barriers to allopathic medicine, and the development and deployment
of effective prehospital care interventions that can improve ‘first mile’ care and sustain life.
WHO will propose engagement with local champions who can lead efforts to introduce
acceptable prehospital ‘first aid’, encourage earlier presentation to primary health care centres,
facilitate safe transport, and provide basic life-support. Accelerating preclinical and clinical
testing of promising prehospital adjunctive treatments, such as the phospholipase A2 inhibitor,
Varespladib, as part of the WHO SBE research agenda may lead to early improvements in pre-
hospital survival [25]. Coupled with improved training of primary healthcare workers in emer-
gency treatment of SBE, safe referral of envenomed patients, and better access to basic life
support commodities, antivenom, and adjunctive medicines, there is great potential to save
lives in even the most remote settings. In many settings, community-level training about basic
airway protection and safe transport to healthcare could save thousands of lives. The WHO
road map recommends strong local engagement with communities to promote prevention,
safe prehospital care, and improved healthcare-seeking behaviour combined with participation
by traditional healthcare providers within the health system rather than outside it. This would
mirror similar approaches that have been applied in some settings for other diseases such as
Buruli ulcer and malaria [31, 32].
Stronger health systems
Many of the components of a functional and responsive health system needed to improve the
outcomes for snakebite victims are no different to those that improve access to universal
• Deliver cost-mitigation and financing schemes to ensure access to effective treatment
and healthcare.
Actions to ensure long-term sustainability of antivenom supply
• Galvanise LMIC countries to support investment in local antivenom manufacturing;
• Work with communities to improve health-care seeking behaviours, and with govern-
ments to support health worker training and education around the use of antivenoms.
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healthcare for all people. Strengthening healthcare capacity and performance at community
and higher national levels is vital and integral to achieving UHC2030 [33]. There is good evi-
dence that such activities can have a substantial impact on the health of women and children,
two groups who are vulnerable to poor outcomes after SBE due to reduced access and other
factors [34]. Myanmar communities identified improved healthcare accessibility to antiven-
oms and greater affordability of health care as key priorities [35]. In Nepal, rapid access to
healthcare positively improved outcomes after SBE [30, 36]. The SBE-WG agreed that inte-
grated steps that build capacity of healthcare systems to better manage SBE and other diseases
should be prioritised and that synergies should be identified and exploited to advance progress
towards achieving SDGs for health and moving closer to UHC2030. The components that are
directly relevant to snakebite victims range from access to prehospital care and ambulance
transport through to effective diagnosis, the availability in hospital of essential medicines
(including antivenoms), consumables and medical services (emergency, intensive care, radiol-
ogy, pathology, renal care, paediatrics, surgical, etc.), complemented by rehabilitation and
recovery support. There was strong agreement that increasing access to clear guidelines that
standardise the diagnosis and treatment of snakebite patients and improving the training of
doctors and other health workers was fundamental to ensuring better outcomes for patients.
The road map calls for countries to increase training for all health workers in an integrated
manner and to work towards improving infrastructure and resourcing of health facilities—
steps that benefit entire communities.
One of the major difficulties associated with SBE is the relative paucity of high quality epi-
demiological surveillance data and the impact this has on being able to accurately report the
burden of disease [2, 3]. Having access to accurate information, research data, and the results
of surveillance is fundamental to health planning, monitoring, and assessment and is a key
component of a strong health system and the elimination or control of NTDs [36, 37]. Glob-
ally, much needs to be done to improve the surveillance of SBE. Under the proposed road
map, WHO will recommend inclusion of SBE as a ‘notifiable disease’. To support adoption of
this designation, and to improve data quality and comparability, standardised clinical criteria
adapted to specific regional needs will be developed and minimum data set definitions for
community-acquired and hospital-acquired data introduced. A number of public health tools
already used to control other diseases can be valuably adopted for building higher resolution
systems to monitor progress to control SBE [38–40]. Research to develop and deploy new
data-collection tools, or which broaden our knowledge of the health- and socio-economic
impacts of SBE, the cost-benefit and cost-effectiveness of interventions, patient care financing,
and effective monitoring and evaluation of road map progress is needed. The WHO will
include SBE data in the Global Health Observatory (www.who.int/gho/) repository and will
work with countries and partners to improve the collection, analysis, and reporting of surveil-
lance data.
Partnership, coordination and resources
Achieving the ambitious goal of reducing SBE mortality and disability by 50% by 2030 requires
strong leadership from WHO, provision of requisite funding, identification and allocation of
adequate resources, and the development of a dynamic global partnership to drive policy
change, implementation, and evaluation of outcomes. Building a strong multidisciplinary and
participatory collaboration is essential to increase effectiveness of interventions and mobilise
resources to reduce the burden of SBE [41, 42]. Effective advocacy, built on robust data, will be
vital to generate and mobilise the resources needed to implement the road map and to ulti-
mately ensure the sustainability of the approaches being proposed. Stimulating research in
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priority areas where there are currently major gaps will ensure that appropriate tools are devel-
oped, and creating strategic partnerships will help ensure that research outcomes are effectively
translated into new clinical and public health tools to reduce the burden of SBE.
The resolution on SBE (WHA71.5) passed at the 71st World Health Assembly in May 2018
robustly calls on countries to increase their efforts to prevent and control this disease, just as it
requests that WHO also takes specific steps in this regard [17]. The WHO road map for SBE
will set out pathways for the incorporation of this disease in regional- and country-level health
plans and will focus on horizontal integration, complementary activities, and local stakeholder
inclusion and participation. In-country and regional coordination mechanisms that integrate
SBE with interventions for other diseases, such as wound care programmes for Buruli ulcer
[43], promotion of footwear to prevent soil-associated diseases such as hookworm or podoco-
niosis [44], or the use of malaria bed nets (which can prevent nocturnal snakebites in places
where people are sleeping) [45] will be promoted. Similarly, the success of programmes such
as WASH that improve sanitation and human behaviours can help to reduce the risk of SBE
[46].
Next steps and key actions
The road map has been revised by the SBE-WG and will be shared with key stakeholders
before it is published and officially launched in May 2019. WHO is preparing a budget for
implementing resolution WHA71.5, which will require strong financial commitment from
stakeholders. The roll-out of the road map is incremental, and as efforts scale up, the strategy
will require increased investment to support expanded WHO activities and in-country imple-
mentation. Additional modelling of implementation costs and benefits of specific components
of the strategy are being undertaken, and together with the road map, these will be used to
make the investment case for prevention, control, and reduction of SBE.
The challenge of building an argument for an NTD that cannot be eliminated, and for
which no single universal ‘cure’ is available, is substantial. But the reality is that there is good
evidence demonstrating that effective treatment can dramatically reduce mortality by as much
as 85% to 88% and also increase positive healthcare-seeking behaviours [47, 48]. In contrast to
some other NTD vectors, venomous snakes cannot be eliminated, but SBE can be effectively
prevented and controlled so that the burden of injury and the impact on those affected are sub-
stantially reduced. Funding is the only barrier to achieving rapid positive and sustainable
change. A strong transformational funding investment from both public and private sectors
that addresses the short-, medium-, and long-term needs of delivering effective solutions can
ensure that SBE becomes a global public health success story. The WHO strategy of improving
the production, quality control, and regulation of these life-saving medicines through a com-
prehensive program to stimulate modernisation, research and development, and to reinvigo-
rate the market, represents a strong advance on the road to achieving a 50% reduction in
global mortality and disability and is a compelling case for such investment. Combined with
parallel efforts on community engagement and education, health systems strengthening
towards universal healthcare and SDG3, effective partnerships at local, national, regional, and
global level, and critically-needed funding, the WHO SBE road map can be transformative and
enable many of the world’s poorest and most vulnerable communities to have a chance at liv-
ing healthy and productive lives.
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